Landmark successes, such as trastuzumab for HER2-positive breast cancer and imatinib for chronic myeloid leukemia, demonstrated that patients sharing specific genetic profiles could benefit from tailored treatments [10,11]. This evidence concerns the gene ERBB2 and breast carcinoma.